Ulrich Kintscher

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1142303/publications.pdf

Version: 2024-02-01

91 papers 5,060 citations

147801 31 h-index 91884 69 g-index

95 all docs 95 docs citations

95 times ranked 6969 citing authors

#	Article	IF	Citations
1	Angiotensin Type 1 Receptor Blockers Induce Peroxisome Proliferator–Activated Receptor-γ Activity. Circulation, 2004, 109, 2054-2057.	1.6	696
2	Gender in cardiovascular diseases: impact on clinical manifestations, management, and outcomes. European Heart Journal, 2016, 37, 24-34.	2.2	512
3	Molecular Characterization of New Selective Peroxisome Proliferator-Activated Receptor Â Modulators With Angiotensin Receptor Blocking Activity. Diabetes, 2005, 54, 3442-3452.	0.6	270
4	PPARÎ ³ -Activating Angiotensin Type-1 Receptor Blockers Induce Adiponectin. Hypertension, 2005, 46, 137-143.	2.7	257
5	Angiotensin II Type 2 Receptor Stimulation. Circulation, 2008, 118, 2523-2532.	1.6	250
6	Metabolic Actions of Estrogen Receptor Beta ($ER\hat{l}^2$) are Mediated by a Negative Cross-Talk with PPAR \hat{l}^3 . PLoS Genetics, 2008, 4, e1000108.	3 . 5	241
7	Female sex and estrogen receptor- \hat{l}^2 attenuate cardiac remodeling and apoptosis in pressure overload. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2010, 298, R1597-R1606.	1.8	205
8	PPAR \hat{I}^3 -mediated insulin sensitization: the importance of fat versus muscle. American Journal of Physiology - Endocrinology and Metabolism, 2005, 288, E287-E291.	3.5	196
9	Peroxisome Proliferator-activated Receptor γ Ligands Inhibit Retinoblastoma Phosphorylation and G1 → S Transition in Vascular Smooth Muscle Cells. Journal of Biological Chemistry, 2000, 275, 22435-22441.	3.4	195
10	Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone's Antifibrotic Activity. Hypertension, 2018, 71, 599-608.	2.7	149
11	Metabolic impact of estrogen signalling through ERalpha and ERbeta. Journal of Steroid Biochemistry and Molecular Biology, 2010, 122, 74-81.	2.5	138
12	Regulation of Peroxisome Proliferator–Activated Receptor γ Activity by Losartan Metabolites. Hypertension, 2006, 47, 586-589.	2.7	86
13	Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: A sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients. Cardiovascular Diabetology, 2007, 6, 12.	6.8	81
14	Angiotensin Type 2 Receptor Stimulation Ameliorates Left Ventricular Fibrosis and Dysfunction via Regulation of Tissue Inhibitor of Matrix Metalloproteinase $1/M$ atrix Metalloproteinase 9 Axis and Transforming Growth Factor \hat{I}^21 in the Rat Heart. Hypertension, 2014, 63, e60-7.	2.7	72
15	Cannabinoid receptor 1 inhibition improves cardiac function and remodelling after myocardial infarction and in experimental metabolic syndrome. Journal of Molecular Medicine, 2013, 91, 811-823.	3.9	69
16	Novel nonâ€steroidal mineralocorticoid receptor antagonists in cardiorenal disease. British Journal of Pharmacology, 2022, 179, 3220-3234.	5.4	65
17	PPARα Inhibits TGF-β–Induced β 5 Integrin Transcription in Vascular Smooth Muscle Cells by Interacting With Smad4. Circulation Research, 2002, 91, e35-44.	4.5	62
18	Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists Cause Differential Cardiac Gene Expression in Pressure Overload-induced Cardiac Hypertrophy. Journal of Cardiovascular Pharmacology, 2016, 67, 402-411.	1.9	59

#	Article	IF	CITATIONS
19	Plasma Angiotensin Peptide Profiling and ACE (Angiotensin-Converting Enzyme)-2 Activity in COVID-19 Patients Treated With Pharmacological Blockers of the Renin-Angiotensin System. Hypertension, 2020, 76, e34-e36.	2.7	57
20	Sex differences in physiological cardiac hypertrophy are associated with exercise-mediated changes in energy substrate availability. American Journal of Physiology - Heart and Circulatory Physiology, 2011, 301, H115-H122.	3 . 2	56
21	elF5A hypusination, boosted by dietary spermidine, protects from premature brain aging and mitochondrial dysfunction. Cell Reports, 2021, 35, 108941.	6.4	56
22	Sexual Dimorphic Regulation of Body Weight Dynamics and Adipose Tissue Lipolysis. PLoS ONE, 2012, 7, e37794.	2.5	55
23	PPARgamma activation attenuates T-lymphocyte-dependent inflammation of adipose tissue and development of insulin resistance in obese mice. Cardiovascular Diabetology, 2010, 9, 64.	6.8	52
24	Obesity-related hypoxia via miR-128 decreases insulin-receptor expression in human and mouse adipose tissue promoting systemic insulin resistance. EBioMedicine, 2020, 59, 102912.	6.1	52
25	Retinoids Inhibit Proliferation of Human Coronary Smooth Muscle Cells by Modulating Cell Cycle Regulators. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 746-751.	2.4	49
26	Adipose Tissue Lipolysis Promotes Exercise-induced Cardiac Hypertrophy Involving the Lipokine C16:1n7-Palmitoleate. Journal of Biological Chemistry, 2015, 290, 23603-23615.	3.4	49
27	Adipose tissue ATGL modifies the cardiac lipidome in pressure-overload-induced left ventricular failure. PLoS Genetics, 2018, 14, e1007171.	3.5	42
28	Characterization of New PPARγ Agonists: Analysis of Telmisartan's Structural Components. ChemMedChem, 2009, 4, 445-456.	3.2	38
29	Sex- and age-dependent effects of Gpr30 genetic deletion on the metabolic and cardiovascular profiles of diet-induced obese mice. Gene, 2014, 540, 210-216.	2.2	38
30	Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders â^ New perspectives for combination therapy. Pharmacological Research, 2021, 172, 105859.	7.1	37
31	PCSK9 regulates the chemokine receptor CCR2 on monocytes. Biochemical and Biophysical Research Communications, 2017, 485, 312-318.	2.1	36
32	Sex differences in exercise-induced cardiac hypertrophy. Pflugers Archiv European Journal of Physiology, 2013, 465, 731-737.	2.8	32
33	Angiotensin II, PPAR-Gamma and atherosclerosis. Frontiers in Bioscience - Landmark, 2004, 9, 359.	3.0	31
34	High-Dose Treatment With Telmisartan Induces Monocytic Peroxisome Proliferator-Activated Receptor-Î ³ Target Genes in Patients With the Metabolic Syndrome. Hypertension, 2011, 58, 725-732.	2.7	31
35	Does adiponectin resistance exist in chronic heart failure?. European Heart Journal, 2007, 28, 1676-1677.	2,2	27
36	The Role of Adipose Triglyceride Lipase and Cytosolic Lipolysis in Cardiac Function and Heart Failure. Cell Reports Medicine, 2020, 1, 100001.	6.5	27

3

#	Article	IF	CITATIONS
37	Inhibiting angiotensin type 1 receptors as a target for diabetes. Expert Opinion on Therapeutic Targets, 2008, 12, 1257-1263.	3.4	26
38	Characterization of new PPARγ agonists: Benzimidazole derivatives—importance of positions 5 and 6, and computational studies on the binding mode. Bioorganic and Medicinal Chemistry, 2010, 18, 5885-5895.	3.0	26
39	AT ₂ R (Angiotensin AT2 Receptor) Agonist, Compound 21, Prevents Abdominal Aortic Aneurysm Progression in the Rat. Hypertension, 2018, 72, e20-e29.	2.7	26
40	Application of Speckle-Tracking Echocardiography in an Experimental Model of Isolated Subendocardial Damage. Journal of the American Society of Echocardiography, 2017, 30, 1239-1250.e2.	2.8	25
41	Doxazosin Inhibits Retinoblastoma Protein Phosphorylation and G 1 ât'S Transition in Human Coronary Smooth Muscle Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2000, 20, 1216-1224.	2.4	24
42	Sex-Specific Differences in Type 2 Diabetes Mellitus and Dyslipidemia Therapy: PPAR Agonists. Handbook of Experimental Pharmacology, 2013, , 387-410.	1.8	24
43	Low-Dose Empagliflozin Improves Systolic Heart Function after Myocardial Infarction in Rats: Regulation of MMP9, NHE1, and SERCA2a. International Journal of Molecular Sciences, 2021, 22, 5437.	4.1	24
44	Enhanced insulin signaling in density-enhanced phosphatase-1 (DEP-1) knockout mice. Molecular Metabolism, 2015, 4, 325-336.	6.5	23
45	AT1-receptor blockade attenuates outward aortic remodeling associated with diet-induced obesity in mice. Clinical Science, 2017, 131, 1989-2005.	4.3	23
46	Characterization of Myocardial Microstructure and Function in an Experimental Model of Isolated Subendocardial Damage. Hypertension, 2019, 74, 295-304.	2.7	23
47	TGF- \hat{l}^21 induces peroxisome proliferator-activated receptor \hat{l}^31 and \hat{l}^32 expression in human THP-1 monocytes. Biochemical and Biophysical Research Communications, 2002, 297, 794-799.	2.1	22
48	Characterization of New PPARγ Agonists: Benzimidazole Derivatives - the Importance of Positionâ€2. ChemMedChem, 2009, 4, 1136-1142.	3.2	22
49	New telmisartan-derived PPAR \hat{I}^3 agonists: Impact of the 3D-binding mode on the pharmacological profile. European Journal of Medicinal Chemistry, 2016, 124, 138-152.	5.5	22
50	Sex and Sex Hormone–Dependent Cardiovascular Stress Responses. Hypertension, 2013, 61, 270-277.	2.7	21
51	Evaluation of a commercial multi-dimensional echocardiography technique for ventricular volumetry in small animals. Cardiovascular Ultrasound, 2018, 16, 10.	1.6	21
52	Pharmacological inhibition of adipose tissue adipose triglyceride lipase by Atglistatin prevents catecholamine-induced myocardial damage. Cardiovascular Research, 2022, 118, 2488-2505.	3.8	20
53	Reuptake Inhibitors of Dopamine, Noradrenaline, and Serotonin. Handbook of Experimental Pharmacology, 2012, , 339-347.	1.8	18
54	A Polymorphic Microsatellite Repeat within the ECE-1c Promoter Is Involved in Transcriptional Start Site Determination, Human Evolution, and Alzheimer's Disease. Journal of Neuroscience, 2012, 32, 16807-16820.	3.6	17

#	Article	IF	CITATIONS
55	Sex Differences in Cardiac Mitochondria in the New Zealand Obese Mouse. Frontiers in Endocrinology, 2018, 9, 732.	3.5	17
56	p38 MAP kinase negatively regulates angiotensin II-mediated effects on cell cycle molecules in human coronary smooth muscle cells. Biochemical and Biophysical Research Communications, 2003, 305, 552-556.	2.1	16
57	Effect of high-dose valsartan on inflammatory and lipid parameters in patients with Type 2 diabetes and hypertension. Diabetes Research and Clinical Practice, 2010, 89, 209-215.	2.8	14
58	Cardiovascular magnetic resonance feature tracking in small animals $\hat{a} \in \hat{a}$ a preliminary study on reproducibility and sample size calculation. BMC Medical Imaging, 2017, 17, 51.	2.7	13
59	INT-131, a PPARgamma agonist for the treatment of type 2 diabetes. Current Opinion in Investigational Drugs, 2009, 10, 381-7.	2.3	13
60	Pharmacological Differences of Glitazones. Journal of the American College of Cardiology, 2008, 52, 882-884.	2.8	12
61	ONTARGET, TRANSCEND, and PRoFESS: new-onset diabetes, atrial fibrillation, and left ventricular hypertrophy. Journal of Hypertension, 2009, 27, S36-S39.	0.5	12
62	Inhibition of Src homology 2 domainâ€containing phosphatase 1 increases insulin sensitivity in highâ€fat dietâ€induced insulinâ€resistant mice. FEBS Open Bio, 2016, 6, 179-189.	2.3	12
63	Speckle-tracking echocardiography combined with imaging mass spectrometry assesses region-dependent alterations. Scientific Reports, 2020, 10, 3629.	3.3	12
64	High-Mobility Group A1 Protein. Circulation Research, 2012, 110, 394-405.	4.5	11
65	Accurate assessment of LV function using the first automated 2D-border detection algorithm for small animals - evaluation and application to models of LV dysfunction. Cardiovascular Ultrasound, 2019, 17, 7.	1.6	11
66	Fat-body brummer lipase determines survival and cardiac function during starvation in Drosophila melanogaster. IScience, 2021, 24, 102288.	4.1	11
67	Use of fixed-dose combination antihypertensives in Germany between 2016 and 2020: an example of guideline inertia. Clinical Research in Cardiology, 2023, 112, 197-202.	3.3	11
68	Targeting density-enhanced phosphatase-1 (DEP-1) with antisense oligonucleotides improves the metabolic phenotype in high-fat diet-fed mice. Cell Communication and Signaling, 2013, 11, 49.	6.5	9
69	ACE2 and SARS-CoV-2: Tissue or Plasma, Good or Bad?. American Journal of Hypertension, 2021, 34, 274-277.	2.0	9
70	Importance of 5/6-aryl substitution on the pharmacological profile of $4\hat{E}^{1}$ -((2-propyl-1H-benzo[d]imidazol-1-yl)methyl)-[1,1 \hat{E}^{1} -biphenyl]-2-carboxylic acid derived PPARγ agonists. European Journal of Medicinal Chemistry, 2017, 126, 590-603.	5.5	8
71	Effects of empagliflozin and target-organ damage in a novel rodent model of heart failure induced by combined hypertension and diabetes. Scientific Reports, 2020, 10, 14061.	3.3	8
72	Hypertrophy-Reduced Autophagy Causes Cardiac Dysfunction by Directly Impacting Cardiomyocyte Contractility. Cells, 2021, 10, 805.	4.1	8

#	Article	IF	CITATIONS
73	Serelaxin Improves Regional Myocardial Function in Experimental Heart Failure: An In Vivo Cardiac Magnetic Resonance Study. Journal of the American Heart Association, 2020, 9, e013702.	3.7	7
74	Characterization of Telmisartanâ€Derived PPARγ Agonists: Importance of Moiety Shift from Positionâ€6 toâ€! on Potency, Efficacy and Cofactor Recruitment. ChemMedChem, 2012, 7, 1935-1942.	5 3 . 2	6
7 5	High-Fat Diet Induces Unexpected Fatal Uterine Infections in Mice with aP2-Cre-mediated Deletion of Estrogen Receptor Alpha. Scientific Reports, 2017, 7, 43269.	3.3	6
76	Adipose tissue–heart crosstalk as a novel target for treatment of cardiometabolic diseases. Current Opinion in Pharmacology, 2021, 60, 249-254.	3.5	6
77	Cardioprotective Effects of Palmitoleic Acid (C16:1n7) in a Mouse Model of Catecholamine-Induced Cardiac Damage Are Mediated by PPAR Activation. International Journal of Molecular Sciences, 2021, 22, 12695.	4.1	6
78	Finerenone Reduces Renal RORγt γδT Cells and Protects against Cardiorenal Damage. American Journal of Nephrology, 2022, 53, 552-564.	3.1	6
79	Spontaneous Degenerative Aortic Valve Disease in New Zealand Obese Mice. Journal of the American Heart Association, 2021, 10, e023131.	3.7	5
80	Assessment of Myocardial Microstructure in a Murine Model of Obesity-Related Cardiac Dysfunction by Diffusion Tensor Magnetic Resonance Imaging at 7T. Frontiers in Cardiovascular Medicine, 2022, 9, 839714.	2.4	5
81	Benefit of Blood Pressure Control in Diabetic Patients. Current Hypertension Reports, 2015, 17, 50.	3.5	4
82	Development and implementation of blood pressure screening and referral guidelines for German community pharmacists. Journal of Clinical Hypertension, 2020, 22, 1807-1816.	2.0	4
83	Liver X Receptor Agonist AZ876 Induces Beneficial Endogenous Cardiac Lipid Reprogramming and Protects Against Isoproterenolâ€Induced Cardiac Damage. Journal of the American Heart Association, 2021, 10, e019473.	3.7	4
84	Depletion of cardiac cardiolipin synthase alters systolic and diastolic function. IScience, 2021, 24, 103314.	4.1	4
85	Wt1 haploinsufficiency induces browning of epididymal fat and alleviates metabolic dysfunction in mice on high-fat diet. Diabetologia, 2022, 65, 528-540.	6.3	3
86	And in the end—Telmisartan directly binds to PPARγ. Hypertension Research, 2012, 35, 704-705.	2.7	2
87	The cytoskeleton in â€~couch potato-ism': Insights from a murine model of impaired actin dynamics. Experimental Neurology, 2018, 306, 34-44.	4.1	2
88	"Dear Doctor―Warning Letter (Rote-Hand-Brief) on Hydrochlorothiazide and Its Impact on Antihypertensive Prescription. Deutsches Ärzteblatt International, 2020, 117, 687-688.	0.9	2
89	The Individualized Obesity Paradox. Journal of the American College of Cardiology, 2014, 63, 786-787.	2.8	1
90	Myocardial Infarction After High-Dose Catecholamine Application—A Case Report From an Experimental Imaging Study. Frontiers in Cardiovascular Medicine, 2020, 7, 580296.	2.4	1

ARTICLE IF CITATIONS

91 Metabolic Effects of AT2R Stimulation inÂAdipose Tissue. , 2015, , 119-123. 0